度拉糖肽对2型糖尿病患者体重指数影响的Meta分析

Meta-analysis of the effect of Dulotide on body mass index in type 2 diabetes patients

目的评价度拉糖肽对2型糖尿病(T2DM)患者体重指数(BMI)的影响。方法计算机检索中国知网、维普网、万方数据库以及PubMed、Web of Science、EMBASE、Scopus、Google Scholar等数据库,收集度拉糖肽对T2DM患者BMI影响的随机对照试验(RCT)。检索时间为建库至2023年2月。根据Cochrane偏倚风险工具评估偏倚风险,Revman 5.3.0软件进行Meta分析。结果共纳入7项RCT文献,573例受试者,其中试验组285例,对照组288例。Meta分析结果显示,度拉糖肽能改善T2DM患者的BMI,差异具有统计学意义[WMD=-0.75,95%CI:(-1.17,-0.34),P=0.0003]。结论度拉糖肽可能降低T2MD患者的BMI,但受限于纳入文献质量及数量,仍需高质量多中心的RCT加以验证。

Objective To evaluate the effect of Dulotide on body mass index(BMI)in patients with type 2 diabetes mellitus(T2DM).Methods Randomized controlled trial(RCT)of the effects of Dulotide on BMI in T2DM patients were collected through computer searches of CNKI,Wipp,Wanfang database,PubMed,Web of Science,EMBASE,Scopus,Google Scholar and other databases.The retrieval period is from the establishment of the database to February 2023.The risk of bias was assessed according to the Cochrane Bias Risk Tool.Meta analysis was performed by Revman 5.3.0 software.Results A total of 7 RCT references with 573 subjects were included,there were 285 cases in the experimental group and 288 cases in the control group.The results of Meta analysis showed that Dulotide could improve the BMI of T2DM patients,the difference was statistically significant.Conclusion Dulotide can reduce the BMI of T2MD patients.Due to the limitation of the quality and quantity of the included documents,high-quality multi-center RCTS are needed for validation.